SANOFI BAILS ON RETINOSTAT
Transgene seeks new taker for TG4010 as Novartis opts out
By Cormac Sheridan
Wednesday, April 30, 2014
Shares in Transgene SA dropped 15 percent Tuesday as Novartis AG decided not to trigger an option on its therapeutic vaccine TG4010, which is currently undergoing a phase IIb/III trial in non-small-cell lung cancer (NSCLC).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.